To test whether our in vitro assay could determine the most suitable ASO sequence at the protein level, we used DZNep-treated MYOD1-UDCs derived from two DMD patients with a deletion in exon 45 or 45–54 (DMD-1 and 2 in Table 1), amenable to exon 44 skipping, with various PMOs targeting different exons. Here, MYOD1 is linked to Duchenne muscular dystrophy.